InsiderPulse
Dashboard

MRNA

Moderna, Inc.

Health CareS&P 500

Moderna, Inc. insider trading

Moderna, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Cambridge, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent MRNA insider transactions

5 insiders traded MRNA on the open market between May 15, 2026 and Sep 15, 2026 — 14 sales worth $55.1M, of which 13 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$55.1M

13 of 14 on a 10b5-1 plan

Net
−$55.1M
Insiders
5

Open-market purchases (code P) and sales (code S) from Moderna, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 21, 2026. The live dashboard shows new filings the moment they clear.

Every MRNA Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

MRNA insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded MRNA on the open market: 3 purchases worth $6M and 47 sales worth $25.1M, 45 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 9 sales ($15.5M), by 4 insiders.

QuarterBoughtSold
Q2 2026—−$6.2M5 sales · 4 on a plan
Q1 2026—−$8.5M2 sales · all on a plan
Q4 2025—−$717.3K2 sales · 1 on a plan
Q3 2025——
Q2 2025—−$8.7K1 sale · all on a plan
Q1 2025+$6M3 buys—
Q4 2024—−$231.7K8 sales · all on a plan
Q3 2024—−$9.4M29 sales · all on a plan
Largest purchase
+$3.2M of MRNA by Bancel Stephane (Chief Executive Officer · Director) on Mar 03, 2025.
Largest sale
−$7.8M of MRNA by Hoge Stephen (President) on Feb 23, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Hussain Abbas10b5-1

    Director

    −$265K

    May 01, 2026

    5,682 sh · $46.63

  • Klinger Shannon Thyme10b5-1

    Chief Legal Officer

    −$726K

    Mar 02, 2026

    13,885 sh · $52.29

  • Hoge Stephen10b5-1

    President

    −$7.8M

    Feb 23, 2026

    160,009 sh · $48.84

  • Afeyan Noubar

    Director

    −$703.4K

    Dec 11, 2025

    23,853 sh · $29.49

  • Hussain Abbas10b5-1

    Director

    −$13.9K

    Dec 09, 2025

    504 sh · $27.60

  • Hussain Abbas10b5-1

    Director

    −$8.7K

    Jun 11, 2025

    312 sh · $28.00

  • Bancel Stephane

    Chief Executive Officer · Director

    +$3.2M

    Mar 03, 2025

    102,821 sh · $31.04

  • Bancel Stephane

    Chief Executive Officer · Director

    +$1.8M

    Mar 03, 2025

    57,493 sh · $31.53

  • Sagan Paul

    Director

    +$1M

    Mar 03, 2025

    31,620 sh · $31.76

  • Klinger Shannon Thyme10b5-1

    Chief Legal Officer

    −$23.6K

    Dec 09, 2024

    529 sh · $44.68

  • Hoge Stephen10b5-1

    President

    −$13.6K

    Dec 03, 2024

    314 sh · $43.30

  • Klinger Shannon Thyme10b5-1

    Chief Legal Officer

    −$4.9K

    Dec 03, 2024

    112 sh · $43.30

  • Mock James M10b5-1

    Chief Financial Officer

    −$60.8K

    Nov 29, 2024

    1,420 sh · $42.79

  • Klinger Shannon Thyme10b5-1

    Chief Legal Officer

    −$60.7K

    Nov 29, 2024

    1,418 sh · $42.79

  • Hoge Stephen10b5-1

    President

    −$12.5K

    Nov 29, 2024

    291 sh · $42.79

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Moderna, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001682852
Previously filed as
Moderna Therapeutics, Inc.

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought MRNA

What the stock actually did in the 90 days following each open-market purchase

Don't check MRNA — let it ping you

Get told the moment an insider moves on MRNA

Pro watches Moderna, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add MRNA to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track MRNA on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read MRNA insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

BIIBILMNIDXXIQVAWSTRMDDXCMALGNEWBAXZBH
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are MRNA insiders buying or selling?
Between May 15, 2026 and Sep 15, 2026, 5 Moderna, Inc. insiders made no open-market purchases and 14 sales worth $55.1M, a net sale of $55.1M. 13 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much MRNA stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Moderna, Inc. insiders made 3 open-market purchases worth $6M and 47 sales worth $25.1M. 45 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 9 sales ($15.5M). The largest purchase was Bancel Stephane buying $3.2M on Mar 03, 2025. The largest sale was Hoge Stephen selling $7.8M on Feb 23, 2026.
What was the largest recent MRNA insider trade?
Bancel Stephane (Chief Executive Officer · Director) sold $11M of MRNA stock on Aug 05, 2026 at about $58.79 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy MRNA shares?
No open-market purchase by a Moderna, Inc. insider appears in the filings from May 15, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Bancel Stephane buying $3.2M on Mar 03, 2025.
Where does MRNA insider trading data come from?
From the Form 4 filings Moderna, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.